Injectible biomaterials derived from highly purified bovine dermal collagen have proven to be effective in soft-tissue augmentation with minimal adverse experiences. Indeed, cross-linked collagens have been used for correction of defects of diverse etiologies from dermal rhytids to submucosal defects in vocal cords, lower esophageal sphincters, and urinary sphincters. In multicenter clinical trials in over 200 patients, Contigen™ Bard® collagen implant has proven to be highly biocompatible with surrounding host tissue structures and effective in treating male and female patients with bladder outlet deficiencies as well as female patients with urethral hypermobility. The adverse experiences among treated subjects were of low frequency and clinically unremarkable. Only 1 patient experienced a local hypersensitivity reaction with temporary minor urinary retention that was easily managed. No long-term sequelae resulted. These data demonstrate that Contigen collagen can be safe and effective in the treatment of male and female urinary incontinence of varied etiologies.